Trials / Completed
CompletedNCT00717678
A Randomized Study to Assess the Safety and Efficacy of Prograf vs Prograf-XL in de Novo Kidney Transplant Recipients
A Randomized, Open-Label, Comparative, Multi-Center Study to Assess the Safety and Efficacy of Prograf (Tacrolimus)/MMF and Extended Release (XL) Tacrolimus /MMF in de Novo Kidney Transplant Recipients
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 73 (actual)
- Sponsor
- Astellas Pharma Inc · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to compare the efficacy and safety of Prograf extended release(XL) plus MMF with Prograf plus MMF in de novo kidney transplant recipients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Prograf-XL | oral |
| DRUG | Prograf | oral |
| DRUG | MMF | oral |
Timeline
- Start date
- 2007-12-01
- Primary completion
- 2010-04-01
- Completion
- 2010-04-01
- First posted
- 2008-07-17
- Last updated
- 2015-12-17
Locations
5 sites across 1 country: Taiwan
Source: ClinicalTrials.gov record NCT00717678. Inclusion in this directory is not an endorsement.